Skip to main content
. 2017 Nov 14;8:325. doi: 10.3389/fendo.2017.00325

Figure 1.

Figure 1

Flow chart for the study groups. 105 patients were screened, whereas 62 patients were eligible for the study, of these 33 vs. 29 were randomized to liraglutide vs. glimepiride, respectively. Due to technical hitches and dropouts, there were 26 in the liraglutide vs. 22 in glimepiride group, who were analyzed per-protocol, i.e., full data set.